(Press-News.org) Madrid, 2 december 2010.- Spanish Oncology has established a new standard treatment for Breast Cancer at early stages thanks to the results of the study 9805/Target 0 funded by Spanish Breast Cancer Research Group (GEICAM) and sponsored by Sanofi Aventis.
More than thousand patients and 50 hospitals participated in the study, whose findings are reported in the latest issue of The New England Journal of Medicine. Results indicate that docentaxel during quimotherapy reduces the risk of recurrence by 32% in women with high-risk but node-negative, early stage breast cancer when cancer has not spread to lymph nodes.
The aim of the research was to test the efficiency between a drug combination of docetaxel and cyclophosphamide (TAC) in comparision with the traditional treatment of fluorouracil, doxorubicin and cyclophosphamide (FAC). The research has scientifically supported the Food and Drug Administration (FDA) approval of a new use of docetaxel for Breast Cancer.
"This study represents a hit within Spanish Breast Cancer researches and demonstrates the high-level of Spanish Oncology. For the first time, a National research, developed by an independent research group and with Spanish patients, has established a new Standard treatment for this tumour at early-stages", points out doctor Miguel Martin of Gregorio Marañon Hospital, Madrid. "Apart from this important acknowledge to our scientific labour, it is also important that our research has been published by a prestigious publication such as The New England Journal of Medicine, that only reports those researches which modify standards of treatments".
Improvements on screening campaigns have risen the number of diagnosed women at early stages, just before the tumour has spread to the lymph nodes. However, until now there were no studies with those drug combinations aimed at this profile: women with high-risk but node-negative, early-stage breast cancer. Up to date, we had no approved treatment with taxanos", explains doctor Ana Lluch of Clinico Hospital, Valencia.
"The research launches real figures concerning Breast cancer patients. Treatment benefits were seen in around 70% of patients at early stage and additionally almost 6% patients improved disease-free survival, which means 800 women disease-free per year thanks to this treatment", states doctor Marin. "Up to now, those women were considered low-risk patients and they were not subject of any scientific researches. This concept has been mistaken and caused suboptimal treatments. Thanks to this study we have achieved a new therapeutic tool for a bigger group".
A high-risk of recurrence is considered in the case of women following at least one of the following criteria set by St. Gallen in 1998: patient age of 35 years or older, tumour size greater than 2 cm, negative estrogen-receptor or progesterone-receptor status, tumour histologic grade of 2 or 3.
1060 women participating in the study were randomly assigned to receive TAC or FAC after surgery treated. They received treatment one day every three weeks during six cycles. Scientifics evaluated those criteria: disease-free survival, global survival, treatment security levels and life quality. Results after six years show that adjuvant therapy based on TAC reduce risk of recurrence by 32% and improves disease-free survival. Almost 90% remained disease-free after this period.
For both experts, since now those women will have new alternative therapy. "It is a step towards personalized treatments of this tumour, since the goal is to administrate just those therapies aimed at caused a benefit, avoiding secondary effects. We would thank both women and Spanish Breast Cancer women Federation (FECMA) for all the support. Knowing that one out of eight women will suffer Breast cancer, it is key that all of them are aware of the importance of clinic essays and new researches", explains doctor Miguel Martin.
Eva Carrasco, scientific director of Geicam Fundation, remarks the engagement of this group with scientific investigation, as well as the quality of formation and information. "target 0 started in June 1999, meaning more than 10 years of hard work behind. The study has been created with the collaboration of an independent research group and Sanofi-Aventis, whish demonstrate that those synergies are essential for the development of further effective therapies facing this disease. On behalf of Geicam, we will continue working to guarantee our patients the best treatments in the future".
INFORMATION:
Contacts media:
Mónica Llorente/Mónica Villegas: 91.787.03.00
Roser Trilla Tlf. 91 659 28 70
Spanish Oncology to establish a new standard treatment on breast cancer at early stages
More than a thousand patients and 50 hospitals participated in the study, which represents an important step toward better Spanish breast cancer research
2010-12-04
ELSE PRESS RELEASES FROM THIS DATE:
Farmers slowed down by hunter-gatherers: Our ancestors' fight for space
2010-12-04
Agricultural – or Neolithic – economics replaced the Mesolithic social model of hunter-gathering in the Near East about 10,000 years ago. One of the most important socioeconomic changes in human history, this socioeconomic shift, known as the Neolithic transition, spread gradually across Europe until it slowed down when more northern latitudes were reached.
Research published today, Friday, 3 December 2010, in New Journal of Physics (co-owned by the Institute of Physics and the German Physical Society), details a physical model, which can potentially explain how the spreading ...
Decreased physician reimbursement for hormone therapy may reduce over-treatment of prostate cancer
2010-12-04
The use of androgen suppression therapy (AST) in prostate cancer for low-risk cases declined following a decrease in physician reimbursement, according to a study published online TK in The Journal of the National Cancer Institute. However, the indicated use of AST for metastatic disease in the palliative setting did not decline in the same period.
The use of AST in prostate cancer increased more than threefold between 1991 and 1999 both for patients with metastatic cancer and those with low-risk disease, but AST treatment in the latter group has not been shown to improve ...
Assessing positive outcomes of phase III trials
2010-12-04
Randomized phase III studies should be designed to find out whether a new drug or treatment makes a meaningful difference in patients' survival or quality of life, according to a commentary published online December 3rd in The Journal of the National Cancer Institute. Instead, most trials now are designed to detect a statistically significant difference between treatment and control groups, which may not be clinically meaningful, write Alberto Ocana, M.D., Ph.D. and Ian F. Tannock, M.D., Ph.D., of Princess Margaret Hospital in Toronto.
Regulatory agencies such as the ...
Improvement needed for mastectomy outcome reporting
2010-12-04
Improved standards for outcome reporting in breast reconstruction are needed, according to a review published online December 3rd in The Journal of the National Cancer Institute.
Every year in the United States up to 40% of women with breast cancer undergo a mastectomy. They say the most valuable factor in their decision-making is information from health professionals. However, that information is largely dependent on the quality, reporting, and interpretation of research data on surgical procedures.
To summarize the reporting standards of surgical outcomes in breast ...
Breast CT imaging system marches forward as pain-free tool to aid mammograms
2010-12-04
While questions persist about the best ways to detect breast cancer early, a CT imaging system developed at the University of Rochester Medical Center and first unveiled five years ago is in a better position today to enter the fray -- at least in a supporting role to conventional mammography.
URMC radiologist Avice O'Connell, M.D., was invited to summarize the studies conducted thus far on the Cone Beam Computed Tomography (CBCT) scanner, at the Radiological Society of North America Annual Scientific Assembly in Chicago at 8:30 a.m. (EST) on Friday, December 3, 2010.
O'Connell ...
Anesthetic gases heats climate as much as 1 million cars
2010-12-04
When doctors want their patients asleep during surgery they gently turn the gas tap. But Anaesthetic gasses have a global warming potential as high as a refrigerant that is on its way to being banned in the EU. Yet there is no obligation to report anaesthetic gasses along with other greenhouse gasses such as CO2, refrigerants and laughing gas.
One kilo of anaesthetic gas affects the climate as much as 1620 kilos of CO2. That has been shown by a recent study carried out by chemists from University of Copenhagen and NASA in collaboration with anaesthesiologists from the ...
Dynamics of chaperone protein critical in rescuing brains of Alzheimer's mice from neuron damage
2010-12-04
Tampa, FL (Dec. 3, 2010) -- Dynamic regulation of the chaperone protein Hsp27 was required to get rid of abnormally accumulating tau in the brains of mice genetically modified to develop the memory-choking tau tangles associated with Alzheimer's disease, a University of South Florida-led study found.
Researchers at the USF Health Byrd Alzheimer's Institute demonstrated that the effective switching of Hsp27 between its active and deactivated states was critical on two fronts -- to promote the recycling of the tau protein in healthy nerve cells and to clear abnormal tau ...
Data mining depression
2010-12-04
Could information technology and data mining techniques be used to improve the diagnosis and treatment of depression? That's the question scientists in Australia hope to have answered in a forthcoming issue of the International Journal of Functional Informatics and Personalised Medicine.
Maja Hadzic, Fedja Hadzic and Tharam Dillon of the Digital Ecosystems and Business Intelligence Institute, at Curtin University of Technology, in Perth, explain how depression is rapidly emerging as one of the major health problems now facing society. They add that the World Health Organization ...
Polymeric porous framework of a bismuth citrate-based complex: A potential vehicle for drug delivery
2010-12-04
YANG Nan, MAO ZongWan and SUN HongZhe et al., at the Department of Chemistry, University of Hong Kong and Sun Yat-sen University have characterized a series of bismuth citrate complexes by X-ray crystallography and modeled the structure of ranitidine bismuth citrate, a medicine used widely for the treatment of peptic ulcer and gastric reflux disease. The polymeric framework of bismuth citrate may serve as a "drug carrier" for delivery of other drugs in the human body. This significant contribution is reported in SCIENCE CHINA Chemistry 2010, 53(10).
Elements that possess ...
Faulty gene linked to disorders of sexual development
2010-12-04
Scientists have discovered that the alteration of a single gene could cause some male embryos to develop as females.
The breakthrough will improve diagnosis and clinical management of patients with disorders of sex development (DSD). These conditions occur when the testis or ovary does not develop properly in the embryo, causing genital abnormalities in one in 4500 babies.
An international team including researchers from the Murdoch Childrens Research Institute and the University of Melbourne identified the gene alteration in a group of patients including two families ...
LAST 30 PRESS RELEASES:
QUT scientists create material to turn waste heat into clean power
Major new report sets out how to tackle the ‘profound and lasting impact’ of COVID-19 on cardiovascular health
Cosmic crime scene: White dwarf found devouring Pluto-like icy world
Major report tackles Covid’s cardiovascular crisis head-on
A third of licensed GPs in England not working in NHS general practice
ChatGPT “thought on the fly” when put through Ancient Greek maths puzzle
Engineers uncover why tiny particles form clusters in turbulent air
GLP-1RA drugs dramatically reduce death and cardiovascular risk in psoriasis patients
Psoriasis linked to increased risk of vision-threatening eye disease, study finds
Reprogramming obesity: New drug from Italian biotech aims to treat the underlying causes of obesity
Type 2 diabetes may accelerate development of multiple chronic diseases, particularly in the early stages, UK Biobank study suggests
Resistance training may improve nerve health, slow aging process, study shows
Common and inexpensive medicine halves the risk of recurrence in patients with colorectal cancer
SwRI-built instruments to monitor, provide advanced warning of space weather events
Breakthrough advances sodium-based battery design
New targeted radiation therapy shows near-complete response in rare sarcoma patients
Does physical frailty contribute to dementia?
Soccer headers and brain health: Study finds changes within folds of the brain
Decoding plants’ language of light
UNC Greensboro study finds ticks carrying Lyme disease moving into western NC
New implant restores blood pressure balance after spinal cord injury
New York City's medical specialist advantage may be an illusion, new NYU Tandon research shows
Could a local anesthetic that doesn’t impair motor function be within reach?
1 in 8 Italian cetacean strandings show evidence of fishery interactions, with bottlenose and striped dolphins most commonly affected, according to analysis across four decades of data and more than 5
In the wild, chimpanzees likely ingest the equivalent of several alcoholic drinks every day
Warming of 2°C intensifies Arctic carbon sink but weakens Alpine sink, study finds
Bronze and Iron Age cultures in the Middle East were committed to wine production
Indian adolescents are mostly starting their periods at an earlier age than 25 years ago
Temporary medical centers in Gaza known as "Medical Points" (MPs) treat an average of 117 people daily with only about 7 staff per MP
Rates of alcohol-induced deaths among the general population nearly doubled from 1999 to 2024
[Press-News.org] Spanish Oncology to establish a new standard treatment on breast cancer at early stagesMore than a thousand patients and 50 hospitals participated in the study, which represents an important step toward better Spanish breast cancer research